View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 11, 2020

Triple drug combination shows promise in Covid-19 treatment

Early data from a small trial conducted by the University of Hong Kong has demonstrated promise for the Covid-19 treatment with a combination of HIV medicine lopinavir–ritonavir, hepatitis drug ribavirin, and multiple sclerosis therapy interferon beta.

Early data from a small trial conducted by the University of Hong Kong has demonstrated promise for the Covid-19 treatment with a combination of HIV medicine lopinavir–ritonavir, hepatitis drug ribavirin, and multiple sclerosis therapy interferon beta.

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

The Phase II trial involved 127 patients with mild to moderate symptoms, but not those with severe Covid-19.

Published in the Lancet journal, the trial findings revealed that patients treated with the triple drug combination tested negative for the virus five days earlier than those treated with lopinavir–ritonavir alone at seven days and 12 days respectively.

Secondary outcomes in the trial showed that clinical improvement and length of hospital stay may be significantly shorter with the triple combination, less than seven days after initial symptoms, versus the HIV medication alone.

University of Hong Kong professor Kwok-Yung Yuen said: “Our trial demonstrates that early treatment of mild to moderate Covid-19 with a triple combination of antiviral drugs may rapidly suppress the amount of virus in a patient’s body, relieve symptoms, and reduce the risk to health-care workers by reducing the duration and quantity of viral shedding (when the virus is detectable and potentially transmissible).

“Furthermore, the treatment combination appeared safe and well tolerated by patients. Despite these encouraging findings, we must confirm in larger Phase III trials that interferon beta-1b alone or in combination with other drugs is effective in patients with more severe illness (in whom the virus has had more time to replicate).”

All participants were given standard hospital care during the trial, including ventilation support, dialysis support, antibiotics, and corticosteroids.

Kowk-Yung Yuen added that the findings were ‘encouraging’, but the triple drug combination’s effect must be assessed in larger patient population and in those with severe Covid-19.

Related Companies

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena